Sotyktu (deucravacitinib) has been assigned a Prescription Drug User Fee Act (PDUFA) goal date of March 6, 2026.

BioNTech SE (NASDAQ:BNTX) is one of the 13 Best German Stocks to Invest in Now. It is a clinical-stage biotechnology company focused on immunotherapies to treat cancer and other serious diseases. On ...

Shares of clinical-stage company Summit Therapeutics SMMT rose nearly 9% on Thursday following a report issued by Bloomberg, which stated that pharma giant AstraZeneca AZN is in discussions with the ...

The first half of 2025 has been topsy-turvy for Bristol Myers BMY. Shares of this biotech giant have lost 16.3% year to date compared with the industry ’s decline of 2.7%. The stock has also ...

The designation was granted for BioNTech’s bispecific antibody treatment for small cell lung cancer (SCLC), which appears to be BNT327, also known as PM8002, according to the FDA’s Orphan Drug ...

Key Takeaways BioNTech and Bristol Myers Squibb have entered a major global collaboration to co-develop and co-commercialize BNT327, a bispecific antibody for solid tumors, with $1.5B upfront, $2 ...

BioNTech SE and Bristol Myers Squibb announced that the companies have entered into an agreement for the global co-development and co-commercialization of BioNTech’s investigational bispecific ...

German-based BioNTech , best known for its collaboration with Pfizer during the COVID-19 pandemic for developing vaccines, found itself back in the spotlight this month. The compa ...

On Monday, June 2, Truist Securities analysts raised the price target on BioNTech SE (NASDAQ:BNTX) from $151 to $155 and kept a “Buy” rating. This decision came after the company entered into ...

These risks, assumptions, uncertainties and other factors include, among others, that the expected benefits of, and opportunities related to the collaboration with BioNTech may not be consistent with ...